Pakistan Medicines & Pharma IntelligenceMedicine data  •  Company portfolios  •  Price records
MedInfoBaseMedicines · Evidence · Intelligence
Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

Arreta Pharmaceuticals (Pvt.) Ltd.

Pharmaceutical manufacturer · Pakistan

Database-driven profile Portfolio, price and regulatory-source intelligence derived from MedInfoBase records.
ShareSend this page
Regulatory & corporate identity

Company profile

Not yet verified
Company type
Pharmaceutical manufacturer
DRAP-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000846 80 linked products · source seen 10 Aug 2026 View source ↗
Location intelligence

Company location

Google Maps
Exact site not yet verified

MedInfoBase will not invent a factory or office location. The map appears after a sourced address, Place ID or verified embed URL is added.

Open in Google Maps ↗ The Google Maps search link uses the company name and available city/country context; it is not presented as a verified premises pin.
Intelligence snapshot

Portfolio at a glance

Not sales data · current MedInfoBase database view
Rx80product presentations
G34generic molecules
DF5dosage-form groups
TA9therapeutic areas
PKR80current price records
REG69registration numbers
Data coverage

How complete is this profile?

Current price coverage100%
products with a current official price
Source-linked coverage100%
products linked back to a source record
Unit-price parse coverage100%
priced packs safely normalized per unit
Comparable-market coverage99%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixArreta Pharmaceuticals (Pvt.) Ltd.Share of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/arreta-pharmaceuticals-pvt-ltdGenerated 10 Aug 2026Anti-infectives42 · 53%CNS & mental health17 · 21%Pain & musculoskeletal8 · 10%Gastrointestinal & hepatology5 · 6%Hematology & thrombosis3 · 4%Vitamins, minerals & nutrition2 · 3%Respiratory & allergy1 · 1%Other therapeutic areas2 · 3%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioArreta Pharmaceuticals (Pvt.) Ltd.Distribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/arreta-pharmaceuticals-pvt-ltdGenerated 10 Aug 202680presentationsTablet39 · 49%Suspension16 · 20%Injection13 · 16%Capsule11 · 14%Syrup1 · 1%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent-Market Price Position

Shows whether safely comparable products are below, near or above the market median unit price.

Equivalent-Market Price PositionArreta Pharmaceuticals (Pvt.) Ltd.Current company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/arreta-pharmaceuticals-pvt-ltdGenerated 10 Aug 202679comparable productsBelow market median49 · 62%Near market median26 · 33%Above market median4 · 5%Company median price position-13.2%Lowest-price equivalents7Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsArreta Pharmaceuticals (Pvt.) Ltd.Companies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/arreta-pharmaceuticals-pvt-ltdGenerated 10 Aug 2026Mediate Pharmaceutical Pvt Ltd27 shared79% overlapNeutro Pharma (Pvt.) Ltd.,25 shared74% overlapSAFE PHARMACEUTICAL (PVT) LTD24 shared71% overlapGlobal Pharmaceuticals Pvt Ltd23 shared68% overlapSemos Pharmaceuticals PVT LTD23 shared68% overlapM/s. Genix Pharma (Pvt) Ltd.22 shared65% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives42 products · 53%
CNS & mental health17 products · 21%
Pain & musculoskeletal8 products · 10%
Gastrointestinal & hepatology5 products · 6%
Hematology & thrombosis3 products · 4%
Vitamins, minerals & nutrition2 products · 3%
Respiratory & allergy1 products · 1%
Reproductive & genitourinary1 products · 1%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Third-generation cephalosporins17 products · 21%
Analgesics / NSAIDs8 products · 10%
Antiepileptics7 products · 9%
Fluoroquinolone antibacterials5 products · 6%
Antipsychotics5 products · 6%
Nitroimidazole anti-infectives5 products · 6%
Benzodiazepines / sedatives5 products · 6%
First-generation cephalosporins5 products · 6%
Formulation footprint

Dosage forms

Tablet39 products
Suspension16 products
Injection13 products
Capsule11 products
Syrup1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 CefrreCeftriaxone 7presentations 1 g, 2 g, 250 mg, 500 mg · Injection #2 ArractamLevetiracetam 5presentations 1000 mg, 250 mg, 500 mg, 750 mg · Tablet #3 RetaphalCephalexin 5presentations 125 mg/5 mL, 250 mg, 250 mg/5 mL, 500 mg · Suspension, Capsule #4 BydinMetronidazole 4presentations 200 mg/5 mL, 400 mg · Suspension, Tablet #5 OzymapOmeprazole 4presentations 20 mg, 40 mg · Tablet, Capsule #6 TimolParacetamol 4presentations 120 mg, 120 mg/5 mL, 250 mg/5 mL, 500 mg · Suspension, Tablet
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median4962% of comparable products
Near market median26within ±5% of median
Above market median45% of comparable products
Lowest-price equivalents7ties included
Company median price position -13.2% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Tdpam 2 mgDiazepam · Tablet · 1000's PKR 0.22/tablet-71.2% vs market median Doxireta 50 mgPyridoxine HCl · Tablet · 20's PKR 1.85/tablet-56.6% vs market median Lumereta 80 mg + 480 mgArtemether + Lumefantrine · Tablet · 8's PKR 47.77/tablet-56.2% vs market median Arractam 500 mgLevetiracetam · Tablet · 10's PKR 50.38/tablet-46.4% vs market median Arractam 500 mgLevetiracetam · Tablet · 30's PKR 50.38/tablet-46.4% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Mediate Pharmaceutical Pvt Ltd239 products · 90 generics 27shared generics Neutro Pharma (Pvt.) Ltd.,210 products · 97 generics 25shared generics SAFE PHARMACEUTICAL (PVT) LTD137 products · 53 generics 24shared generics Global Pharmaceuticals Pvt Ltd211 products · 80 generics 23shared generics Semos Pharmaceuticals PVT LTD103 products · 45 generics 23shared generics M/s. Genix Pharma (Pvt) Ltd.290 products · 97 generics 22shared generics
Regulatory & price activity

Observed database signals

Registration numbers69
Price-history records90
Products with price history8
Source records with multiple versions0
Latest MedInfoBase verification9 Aug 2026
Latest effective price date23 Jul 2026
Latest source observation10 Aug 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Sponsored company campaign area · advertising must be clearly disclosed
Complete company portfolio

Products and presentations

80 results
Reset
BrandGenericStrengthFormPackRegistrationOfficial priceUnit priceMarket position
Acetofeine Paracetamol + Caffeine 500 mg + 65 mg Tablet 100's 116294 PKR 439.67 PKR 4.40/tablet Near median
Arelic Folic acid 5 mg Tablet 100's 098434 PKR 107.22 PKR 1.07/tablet 34% above median
Aretadine Loratadine 5 mg/5 mL Syrup 60ml 117649 PKR 56.75 PKR 0.95/mL 43% below median
Arractam Levetiracetam 500 mg Tablet 30's 117743 PKR 1,511.34 PKR 50.38/tablet 46% below median
Arractam Levetiracetam 750 mg Tablet 10's 116301 PKR 806.05 PKR 80.61/tablet 39% below median
Arractam Levetiracetam 1000 mg Tablet 10's 116302 PKR 1,007.56 PKR 100.76/tablet 34% below median
Arractam Levetiracetam 500 mg Tablet 10's 117743 PKR 503.78 PKR 50.38/tablet 46% below median
Arractam Levetiracetam 250 mg Tablet 10's 116300 PKR 364.11 PKR 36.41/tablet 34% below median
Arrefloxacin Levofloxacin 500 mg Tablet 10's 117844 PKR 481.78 PKR 48.18/tablet 39% below median
Arrefloxacin Levofloxacin 250 mg Tablet 10's 117635 PKR 289.53 PKR 28.95/tablet 39% below median
Arrepcin Ciprofloxacin 500 mg Tablet 10's 100670 PKR 345.23 PKR 34.52/tablet 18% below median
Arrepcin Ciprofloxacin 250 mg Tablet 10's 100671 PKR 208.74 PKR 20.87/tablet 17% below median
Arretaz Ceftazidime 250 mg Injection 1's 102719 PKR 159.65 PKR 159.65/vial/unit Near median
Arretaz Ceftazidime 1 g Injection 1's 102718 PKR 441.57 PKR 441.57/vial/unit Near median
Arretaz Ceftazidime 500 mg Injection 1's 099797 PKR 231.22 PKR 231.22/vial/unit Near median
Aryspride Risperidone 2 mg Tablet 10's 117642 PKR 225.83 PKR 22.58/tablet 37% below median
Aryspride Risperidone 4 mg Tablet 10's 117643 PKR 451.67 PKR 45.17/tablet 37% below median
Azereta Azithromycin 250 mg Capsule 6's 098435 PKR 245.68 PKR 40.95/capsule 16% below median
B-Profen Ibuprofen 100 mg/5 mL Suspension 90ml 083603 PKR 66.48 PKR 0.74/mL 22% below median
B-Profen Ibuprofen 100 mg/5 mL Suspension 120ml 083603 PKR 87.33 PKR 0.73/mL 23% below median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and DRAP-source records. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.